Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT03031249
PHASE1/PHASE2

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

Summary

In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose cytarabine(HDAC) regimen while the experimental group receive high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety and efficacy of ATRA and ATO is evaluated.

Key Details

Gender

All

Age Range

14 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2017-02-08

Completion Date

2027-10-15

Last Updated

2025-05-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Cytarabine

Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

DRUG

all-trans retinoic acid

ATRA at a dose of 30mg/㎡/d on day 1-14.

DRUG

Arsenic Trioxide

ATO at a dose of 10mg/d on day 1-14

Locations (1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China